Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Restructuring: 2015-2017

Historic Cash from Restructuring for Altimmune (ALT) over the last 2 years, with Mar 2017 value amounting to -$66,633.

  • Altimmune's Cash from Restructuring rose 66.13% to -$66,633 in Q1 2017 from the same period last year, while for Mar 2017 it was -$267,300, marking a year-over-year increase of 83.35%. This contributed to the annual value of -$397,383 for FY2016, which is 182.49% down from last year.
  • As of Q1 2017, Altimmune's Cash from Restructuring stood at -$66,633, which was down 0.00% from -$66,633 recorded in Q4 2016.
  • Over the past 5 years, Altimmune's Cash from Restructuring peaked at $1.9 million during Q1 2015, and registered a low of -$1.1 million during Q2 2015.
  • Over the past 3 years, Altimmune's median Cash from Restructuring value was -$66,727 (recorded in 2016), while the average stood at $7,307.
  • Over the last 5 years, Altimmune's Cash from Restructuring had its largest YoY gain of 93.93% in 2016, and its largest YoY loss of 762.99% in 2016.
  • Quarterly analysis of 3 years shows Altimmune's Cash from Restructuring stood at -$319,008 in 2015, then soared by 79.11% to -$66,633 in 2016, then surged by 66.13% to -$66,633 in 2017.
  • Its Cash from Restructuring was -$66,633 in Q1 2017, compared to -$66,633 in Q4 2016 and -$67,307 in Q3 2016.